Charles River Laboratories
CRL · NYSE · USD · Healthcare
1What is happening
Charles River Laboratories has fallen 11% since its 6-week high on 29/10/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayfrom the 6-week high-11.1%
Other view · 15 analystsHorizon: 12 months14 Buy · 2 Hold · 1 Sell2Our assessment
Dip in progress36How it continues – phase and signs – you see with a free account.
3Your next step
Marking places no order – it only helps you keep track.
More details · reasons, figures, alerts
How deep is the dip?
- from the 6-week high-11.1%
Highest daily price: $379.63 on 29/10/2026 · reference of the assessment · also the highest of the last 3 months
- from the 52-week high-11.1%
Highest price in 52 weeks: $379.63 (Yahoo)
Why is it down?
quarterly numbers- ·From its 6-week high of $379.63 on 29/10/2026 the price fell 11.1% to $337.52.
- ·The biggest single-day drop was 7.3% on 04/11/2026.
- ·That was right after the quarterly numbers. Results were 4% above expectations, so the market reacted to the outlook or details, not the headline number.
- ·No clear news driver in the last 10 days.
- ·The whole market is down 5.6% from its 60-day high, so part of this is not about the company.
- ·Other Diagnostics & Research stocks we track are down only 5.4% on average, so this is mostly about the company. See all 77 in this sector →
Drops after numbers usually take a few weeks to settle. The score already accounts for the miss.
What analysts expect
Most of the 15 analysts say buy. They look about 12 months ahead – DipCatcher only 14 trading days.
- Buy
- 1482 %
- Hold
- 212 %
- Sell
- 16 %
Average price target$333.53
$145.00 to $390.00 · today $337.52
$145.00Ø $333.53$390.00
What is a price target?
The price an analyst expects in about 12 months. Estimates are often far apart and change frequently.
Third-party opinion, not an assessment by DipCatcher. Source: public analyst estimates, as of 08/11/2026. Not financial advice.
The company in figures
- Market value
- 16.2 bn $
- All shares together at the current price.
- P/E
- 366.9
- Price divided by earnings per share, last 12 months.
- 52-week range
- $146.20 – $379.63
- Lowest and highest price of the last year.
Catalysts
36 h ago- News, last 10 days
- no recent news
- Next earnings
- —
- Last report
- 04/11/2026 +3.5% vs estimate
Key figures
- Market value
- 16.2 bn $Large cap
- P/E
- 366.9
- Volume today
- 1.0 × Øabout usual
- Beta
- 1.34swings more than the market
- 52-week range
- $146.20 – $379.63price at 82 % of the range
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Headquarters:
- Wilmington, United States
- 52-week range:
- $146.20 – $379.63
- Website:
- criver.com
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
See which stocks they are
The engine is watching these dips right now. A free account shows the names and opens 3 full analyses a day.
- 3 full analyses a dayWith entry, target, stop and the reasons behind them.
- WatchlistFollow the stocks you care about.
Free, no payment details.
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
Not investment advice. Investing carries risk up to total loss.